



# SonoTran<sup>®</sup> Significantly Increased Tumour Reduction of the anti-PD-L1 Checkpoint Inhibitor in a CT26 Syngeneic Tumour Model

SonoTran<sup>®</sup> has been shown to enhance the delivery of anti-PD-L1 in a preclinical murine model. Eighteen days following treatment, four out of five animals in the SonoTran<sup>®</sup> + PD-L1 Group exhibited significant tumour retardation versus the PD-L1 alone Group. By day twenty eight this culminated in four out of five animals surviving in the SonoTran<sup>®</sup> + PD-L1 compared with no survivors in the PD-L1 alone Group.



Tumour volumes post treatment. Curves represent individual mice.

#### About OxSonics

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran<sup>®</sup> Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran<sup>®</sup> is being evaluated clinically and we're working with multiple partners to tackle the toughest cancers, head on.

#### Partner with us

By combining your therapeutic agent with SonoTran<sup>®</sup> we could significantly de-risk your clinical development program and maximise its chances of delivering first-in-class and/or best-in-class therapy to patients. Importantly no drug reformulation is needed whatsoever.

By working with us, we can create new IP and optimal pricing and reimbursement that together provide a framework to bring better and smarter therapies to patients.

Call:

+44 (0) 1865 784777

Email:

nicholas.adams@oxsonics.com

#### OxSonics Ltd

The Magdalen Centre  
Oxford Science Park  
Robert Robinson Avenue  
Oxford, OX4 4GA  
UK

www.oxsonics.com